RCAP
PTGX icon

Resolute Capital Asset Partners’s Protagonist Therapeutics PTGX Stock Holding History

Resolute Capital Asset Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-39,500
Closed -$1.14M – 59
2024
Q1 		$1.14M Buy
+39,500
New +$1.07M 0.6% 39
2022
Q1 		– Sell
-55,000
Closed -$1.88M – 54
2021
Q4 		$1.88M Buy
+55,000
New +$1.74M 1.23% 33

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Resolute Capital Asset Partners's PTGX Position: Q2 2024 in Review

Resolute Capital Asset Partners sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 39,500 shares — an estimated $1.14M sold.

Resolute Capital Asset Partners first reported a position in PTGX in Q4 2021 and held it in 2 quarters. The position peaked at $1.88M in Q4 2021. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Resolute Capital Asset Partners reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 39,500 Protagonist Therapeutics shares in Q2 2024, an estimated $1.14M.
  • Resolute Capital Asset Partners first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 2 quarters.
  • Resolute Capital Asset Partners's Protagonist Therapeutics position peaked at $1.88M in Q4 2021.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Resolute Capital Asset Partners's 13F filing for Q2 2024, filed 12 Aug 2024.